Missed opportunities for hepatitis c testing in opioid treatment programs

American Journal of Public Health

Volumn 103, Issue 6, 2013, Pages 1028-1030

  Frimpong, Jemima A ^a  

^a Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NARCOTIC ANALGESIC AGENT;

ARTICLE; BLOOD EXAMINATION; DRUG DEPENDENCE TREATMENT; HEALTH CARE DELIVERY; HEALTH CARE SURVEY; HEPATITIS C; HUMAN; MANPOWER; STANDARD; STATISTICS; SUBSTANCE ABUSE; UNITED STATES;

ANALGESICS, OPIOID; HEALTH CARE SURVEYS; HEALTH SERVICES ACCESSIBILITY; HEMATOLOGIC TESTS; HEPATITIS C; HUMANS; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES;

MLCS; MLOWN;

EID: 84878037170     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2012.301129     Document Type: Article

References (25)

1. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156(4):271-278.
2. Wise M, Bialek S, Finelli L, Bell BP, Sorvillo F. Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology. 2008;47(4): 1128-1135.
3. Centers for Disease Control and Prevention. Viral Hepatitis Surveillance-United States, 2009. September 22, 2011.Available at: Http://www.cdc.gov/hepatitis/statistics/2009surveillance/index.htm. Accessed February 2012.
4. Armstrong GL, Wasley AM, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705-714.
5. Dhopesh VP, Taylor KR, Burke WM. Survey of hepatitis B and C in addiction treatment unit. Am J Drug Alcohol Abuse. 2000;26(4):703-707.
6. Cohen MH, Grey D, Cook JA, et al. Awareness of hepatitis C infection among women with and at risk for HIV. J Gen Intern Med. 2007;22(12):1689-1694.
7. Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(suppl 1):S11-S19.
8. Amon JJ, Garfein RS, Ahdieh-Grant L, et al. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clin Infect Dis. 2008;46(12):1852-1858.
9. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47(RR-19):1-39. Available at: Http://www.aidsinfo.nih.gov/contentfiles/Adult-OI. pdf. Accessed August 2012.
10. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. The TEDS Report: Injection Drug Abuse Admissions to Substance Abuse Treatment: 1992 and 2009. Rockville, MD. December 1, 2011. Available at: Http://www.samhsa.gov/data/2k11/WEB-TEDS-012/WEB-TEDS- 012.htm. Accessed August 2012.
11. Vassilev ZP, Strauss SM, Astone JM, Friedmann PD, Des Jarlais DC. Provision of on-site medical care to patients with hepatitis C in drug treatment units. J Health Care Poor Underserved. 2004;15(4):663-671.
12. Burt RD, Thiede H, Hagan H. Serosorting for hepatitis C status in the sharing of injection equipment among Seattle area injection drug users. Drug Alcohol Depend. 2009;105(3):215-220.
13. Hahn JA, Evans JL, Davidson PJ, Lum PJ, Page K. Hepatitis C virus risk behaviors within the partnerships of young injecting drug users. Addiction. 2010;105(7): 1254-1264.
14. D'Aunno T, Pollack HA. Changes in methadone treatment practices: Results from a national panel study, 1988-2000. JAMA. 2002;288(7):850-856.
15. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. The N-SSATS Report: Overview of Opioid Treatment ProgramsWithin the United States: 2008. Rockville, MD: Substance Abuse and Mental Health Services Administration; January 28, 2010. Available at: Http://www.oas.samhsa. gov/2k10/222/222USOTP2k10Web.pdf. Accessed August 2012.
16. Drobnik A, Judd C, Banach D, Egger J, Konty K, Rude E. Public health implications of rapid hepatitis C screening with an oral swab for community-based organizations serving high-risk populations. Am J Public Health. 2011;101(11):2151-2155.
17. D'Aunno T, Vaughn TE, McElroy P. An institutional analysis of HIV prevention efforts by the nation's outpatient drug abuse treatment units. J Health Soc Behav. 1999;40(2):175-192.
18. Pollack HA, D'Aunno T. HIV testing and counseling in the nation's outpatient substance abuse treatment system, 1995-2005. J Subst Abuse Treat. 2010;38(4):307-316.
19. Frankel LR. The report of the CASRO Task Force on response rates. In:Wiseman F, ed. Improving Data Quality in a Sample Survey. Cambridge, MA: Marketing Science Institute; 1983;1-11.
20. Metsch LR, Feaster DJ, Gooden L, et al. Implementing rapid HIV testing with or without risk-reduction counseling in drug treatment centers: Results of a randomized trial. Am J Public Health. 2012;102(6):1160-1167.
21. Harris KA Jr, Arnsten JH, Litwin AH. Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. J Addict Med. 2010;4(1): 20-26.
22. US Food and Drug Administration. FDA News Release: FDA approves rapid test for antibodies to hepatitis C virus. June 25, 2010. Available at: Http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm217318.htm. Accessed April 25, 2012.
23. Bini EJ, Kritz S, Brown LS Jr, et al. Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United States. J Subst Abuse Treat. 2012;42(4):438-445.
24. Marsh KA, Reynolds GL, Rogala BE, Fisher DG, Napper LE. Who chooses a rapid test for HIV in Los Angeles County, California? Eval Health Prof. 2010;33 (2):177-196.
25. Spielberg F, Branson BM, Goldbaum GM, et al. Overcoming barriers to HIV testing: Preferences for new strategies among clients of a needle exchange, a sexually transmitted disease clinic, and sex venues for men who have sex with men. J Acquir Immune Defic Syndr. 2003;32(3):318-327.